Jalaja Joseph1, Robert D Shamburek, Elaine K Cochran, Phillip Gorden, Rebecca J Brown. 1. Diabetes, Endocrinology, and Obesity Branch (J.J., E.K.C., P.G., R.J.B.), National Institute of Diabetes and Digestive and Kidney Diseases, and National Heart Lung and Blood Institute (R.D.S.), National Institutes of Health, Bethesda, Maryland 20892.
Abstract
CONTEXT: There is an inverse relationship between triglycerides and high-density lipoprotein cholesterol (HDL-C) in insulin resistance, such that improvement in insulin resistance decreases triglycerides and increases HDL-C. Patients with lipodystrophy have extreme insulin resistance with high triglycerides and low HDL-C. Leptin replacement in lipodystrophy leads to a marked decrease in triglycerides (∼60%). OBJECTIVE: Our objective was to study the effects of metreleptin on triglycerides and HDL-C in lipodystrophy in contrast to changes in triglycerides and HDL-C in interventions for the obesity-associated metabolic syndrome. DESIGN, SETTING, AND PATIENTS: This open-label nonrandomized study at the National Institutes of Health included 82 patients with various forms of lipodystrophy. INTERVENTION: Metreleptin (0.06-0.24 mg/kg/d) was administered for 24 months in lipodystrophy. MAIN OUTCOME MEASURES: Serum triglycerides and HDL-C were measured. RESULTS: At baseline, lipodystrophy patients had low HDL-C (30 ± 1 mg/dL) and high triglycerides (961 ± 220 mg/dL) with an inverse relationship between the two (R = -0.37, P = .0006). There was no change in HDL-C with metreleptin despite major improvement in triglycerides, and individual changes in triglycerides only weakly predicted HDL-C change. On linear regression, in obesity, a decrease of 0.1 mg/dL in log(triglycerides) was associated with a 4.2 mg/dL rise in HDL-C, whereas in lipodystrophy, a decrease of 0.1 mg/dL in log(triglycerides) was associated with only a 0.6 mg/dL rise in HDL-C. CONCLUSIONS: The normal reciprocal relationship between triglyceride and HDL-C change seen in response to interventions for the obesity-associated metabolic syndrome is quantitatively different from that seen in lipodystrophy in response to metreleptin. Further work is needed to understand HDL-C regulation in this condition.
CONTEXT: There is an inverse relationship between triglycerides and high-density lipoprotein cholesterol (HDL-C) in insulin resistance, such that improvement in insulin resistance decreases triglycerides and increases HDL-C. Patients with lipodystrophy have extreme insulin resistance with high triglycerides and low HDL-C. Leptin replacement in lipodystrophy leads to a marked decrease in triglycerides (∼60%). OBJECTIVE: Our objective was to study the effects of metreleptin on triglycerides and HDL-C in lipodystrophy in contrast to changes in triglycerides and HDL-C in interventions for the obesity-associated metabolic syndrome. DESIGN, SETTING, AND PATIENTS: This open-label nonrandomized study at the National Institutes of Health included 82 patients with various forms of lipodystrophy. INTERVENTION: Metreleptin (0.06-0.24 mg/kg/d) was administered for 24 months in lipodystrophy. MAIN OUTCOME MEASURES: Serum triglycerides and HDL-C were measured. RESULTS: At baseline, lipodystrophy patients had low HDL-C (30 ± 1 mg/dL) and high triglycerides (961 ± 220 mg/dL) with an inverse relationship between the two (R = -0.37, P = .0006). There was no change in HDL-C with metreleptin despite major improvement in triglycerides, and individual changes in triglycerides only weakly predicted HDL-C change. On linear regression, in obesity, a decrease of 0.1 mg/dL in log(triglycerides) was associated with a 4.2 mg/dL rise in HDL-C, whereas in lipodystrophy, a decrease of 0.1 mg/dL in log(triglycerides) was associated with only a 0.6 mg/dL rise in HDL-C. CONCLUSIONS: The normal reciprocal relationship between triglyceride and HDL-C change seen in response to interventions for the obesity-associated metabolic syndrome is quantitatively different from that seen in lipodystrophy in response to metreleptin. Further work is needed to understand HDL-C regulation in this condition.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: A A W Weterings; I A W van Rijsingen; A S Plomp; A H Zwinderman; R H Lekanne Deprez; M M Mannens; M A van den Bergh Weerman; A C van der Wal; S J Pinto-Sietsma Journal: Atherosclerosis Date: 2013-04-20 Impact factor: 5.162
Authors: C E Tan; L Foster; M J Caslake; D Bedford; T D Watson; M McConnell; C J Packard; J Shepherd Journal: Arterioscler Thromb Vasc Biol Date: 1995-11 Impact factor: 8.311
Authors: Andrea Kassai; Ranganath Muniyappa; Amy E Levenson; Mary F Walter; Brent S Abel; Michael Ring; Simeon I Taylor; Sudha B Biddinger; Monica C Skarulis; Phillip Gorden; Rebecca J Brown Journal: J Clin Endocrinol Metab Date: 2016-02-22 Impact factor: 5.958
Authors: Ranganath Muniyappa; Brent S Abel; Asha Asthana; Mary F Walter; Elaine K Cochran; Alan T Remaley; Monica C Skarulis; Phillip Gorden; Rebecca J Brown Journal: J Clin Lipidol Date: 2017-02-24 Impact factor: 4.766
Authors: Amy E Levenson; Mary E Haas; Ji Miao; Rebecca J Brown; Sarah D de Ferranti; Ranganath Muniyappa; Sudha B Biddinger Journal: Endocrinology Date: 2016-01-29 Impact factor: 4.736
Authors: Elif A Oral; Phillip Gorden; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Rebecca J Brown Journal: Endocrine Date: 2019-02-25 Impact factor: 3.633